Prostacyclin is one of the most potent vasoactive autacoids, and is no
w clinically used as an anti-platelet agent, but with limited indicati
ons due to its chemical instability, as well as side effects. A chemic
ally stable prostacyclin derivative (Clinprost) of isocarbacyclin in a
lipid microsphere formulation (TTC-909) was found to be successful wh
en applied in the treatment of various thrombotic diseases, as it disp
enses with problems inherent to naturally occurring prostacyclin.